Press Releases

Press Releases

MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will
May 23, 2022
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review Ocugen’s exclusive territory for COVAXIN™ (BBV152) marketing expanded to include
May 6, 2022
MALVERN, Pa., April 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will
April 19, 2022